Certificate of Supplementary Protection for Pharmaceuticals, Biologics and Veterinary Drugs.Published on November 6, 2017
Author: Bhavesh Patel, C. Chem. Natco Pharma (Canada) Inc.
Health Canada has released the Guidance Document - Certificate of Supplementary Protection Regulations which provides information for industry regarding the recently implemented Certificates of Supplementary for medicinal ingredients.
As part of its obligations under the Comprehensive Economic and Trade Agreement with the European Union, Canada agreed to provide innovators with a period of extended market exclusivity to compensate for the time lost due to regulatory obligations in obtaining market approval. This protection, termed a Certificate of Supplementary Protection, is a form of sui generis exclusivity for up to two years and applies to patents claiming the medicinal ingredient contained in pharmaceuticals, biologics, and veterinary drugs.
An applicant for a CSP must file an application within 120 days from the date of issuance of the Notice of Compliance. At the time of filing, an applicant is required to submit the CSP application form along with advance payment details form and the required fee. The fee for filing a CSP application is $9,011 which is set to increase by 2% per year. The required forms are available on Health Canada’s website.
To be eligible for a CSP, the patent claims must pertain, in the case of a drug containing one medicinal ingredient, to the one medicinal ingredient, or, in the case of a drug containing two or more medicinal ingredients, to the combination of all medicinal ingredients. Please note only one CSP will be granted for a given medicinal ingredient or combination.
Canada Gazette, Part Ⅱ, Ottawa, Registration SOR/2017-165 September 1, 2017 Patent Act, Certificate of Supplementary Protection Regulations
Thank you for reading Regulated Affairs, the CAPRA Blog. CAPRA is a non-profit organization dedicated to providing professional development opportunities in Regulatory Affairs. Feel free to share our blog posts and join us on social media.
Rare Diseases and Orphan Drugs Regulatory Framework in Canada: Recent Initiatives by Government of Canada
What are Rare Diseases and How do They Affect Canadians? According to Health Canada, rare diseases are life-threatening, debilitating, or serious and chronic conditions that...
Health Canada changes filing requirements for product monographs
Did you know, effective immediately, Health Canada is changing the submission requirements for second language product monographs for human drugs? This is for only post-life...
Pragmatic Clinical Trials: Testing Treatments in the Real-World
What is a Pragmatic Clinical Trial? Clinical trials can be designed to be either pragmatic or explanatory. Explanatory trials are designed to find out whether a treatment...